Inflammatory Response Research
Inflammatory Response Research, Inc. (IRR) is a drug development company focused on pharmaceutical products for the treatment of inflammatory disorders and conditions. They are currently developing a safe and effective therapeutic for COVID-19 and a 'First Response' injectable for acute inflammation related to polytrauma and traumatic brain injury, aiming to address unmet medical needs with innovative treatments.
Industries
Nr. of Employees
small (1-50)
Inflammatory Response Research
515 E. Micheltorena, Suite G, Santa Barbara, Ca. 93103
Patents
Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US-9925183-B2
View DetailsUse of levocetirizine and montelukast in the treatment of autoimmune disorders
US-9669026-B2
View DetailsUse of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
US-9044479-B2
View Details
Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US-9925183-B2
View DetailsUse of levocetirizine and montelukast in the treatment of autoimmune disorders
US-9669026-B2
View DetailsUse of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
US-9044479-B2
View DetailsProducts
Oral combination antihistamine + leukotriene receptor antagonist therapy (developmental)
Oral small-molecule combination therapy developed to modulate multiple inflammatory pathways for acute respiratory inflammatory conditions, evaluated in early clinical studies for safety and effects on pulmonary function.
Injectable 'first response' anti-inflammatory for polytrauma / traumatic brain injury (developmental)
Injectable formulation intended for immediate use in acute trauma and traumatic brain injury to attenuate inflammation and support lung function.
Oral combination antihistamine + leukotriene receptor antagonist therapy (developmental)
Oral small-molecule combination therapy developed to modulate multiple inflammatory pathways for acute respiratory inflammatory conditions, evaluated in early clinical studies for safety and effects on pulmonary function.
Injectable 'first response' anti-inflammatory for polytrauma / traumatic brain injury (developmental)
Injectable formulation intended for immediate use in acute trauma and traumatic brain injury to attenuate inflammation and support lung function.
Services
Design and conduct of clinical studies including Phase I execution, safety monitoring, and multicenter randomized trial design.
Preclinical in vitro and in vivo testing, PK/PD profiling, and development of oral and injectable formulations for acute inflammatory indications.
Design and conduct of clinical studies including Phase I execution, safety monitoring, and multicenter randomized trial design.
Preclinical in vitro and in vivo testing, PK/PD profiling, and development of oral and injectable formulations for acute inflammatory indications.
Expertise Areas
- Clinical trial management and execution
- Clinical trial design (randomized, placebo-controlled)
- Preclinical pharmacology and translational research
- Anti-inflammatory small-molecule therapeutic development
Key Technologies
- In vitro antiviral assays
- Animal models (ARDS and acute lung injury)
- Pharmacokinetics / PK profiling
- Pharmacodynamics and receptor occupancy analysis